WallStSmart

Aethlon Medical Inc (AEMD)vsEdwards Lifesciences Corp (EW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 1133973% more annual revenue ($6.51B vs $574,240). EW leads profitability with a 15.4% profit margin vs 0.0%. EW earns a higher WallStSmart Score of 55/100 (C).

AEMD

Hold

39

out of 100

Grade: F

Growth: 6.3Profit: 3.0Value: 6.0Quality: 6.5
Piotroski: 3/9Altman Z: -39.62

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 8.0Value: 5.3Quality: 8.5
Piotroski: 3/9Altman Z: 4.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AEMDUndervalued (+26.1%)

Margin of Safety

+26.1%

Fair Value

$2.83

Current Price

$1.53

$1.30 discount

UndervaluedFair: $2.83Overvalued
EWUndervalued (+68.9%)

Margin of Safety

+68.9%

Fair Value

$254.99

Current Price

$84.37

$170.62 discount

UndervaluedFair: $254.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AEMD3 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
4278.0%10/10

Revenue surging 4278.0% year-over-year

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

EW3 strengths · Avg: 9.3/10
Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
29.8%8/10

Strong operational efficiency at 29.8%

Areas to Watch

AEMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.11M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
1.924/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
51.6x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-25.4%2/10

Earnings declined 25.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : AEMD

The strongest argument for AEMD centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 4278.0% demonstrates continued momentum.

Bull Case : EW

The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.

Bear Case : AEMD

The primary concerns for AEMD are EPS Growth, Market Cap, Profit Margin.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.6x leaves little room for execution misses.

Key Dynamics to Monitor

AEMD profiles as a hypergrowth stock while EW is a mature play — different risk/reward profiles.

AEMD carries more volatility with a beta of 1.40 — expect wider price swings.

AEMD is growing revenue faster at 4278.0% — sustainability is the question.

EW generates stronger free cash flow (585M), providing more financial flexibility.

Bottom Line

EW scores higher overall (55/100 vs 39/100), backed by strong 15.4% margins and 13.6% revenue growth. AEMD offers better value entry with a 26.1% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aethlon Medical Inc

HEALTHCARE · MEDICAL DEVICES · USA

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life- and organ-threatening diseases in the United States. The company is headquartered in San Diego, California.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Want to dig deeper into these stocks?